OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Can the RBD mutation R346X provide an additional fitness to the “variant soup,” including offspring of BQ and XBB of SARS-CoV-2 Omicron for the antibody resistance?
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 61-63
Open Access | Times Cited: 7
Srijan Chatterjee, Manojit Bhattacharya, Kuldeep Dhama, et al.
Molecular Therapy — Nucleic Acids (2023) Vol. 32, pp. 61-63
Open Access | Times Cited: 7
Showing 7 citing articles:
Another variant another history: description of the SARS-CoV-2 KP.2 (JN.1.11.1.2) mutations
Francesco Branda, Alessandra Ciccozzi, Chiara Romano, et al.
Infectious Diseases (2024) Vol. 56, Iss. 7, pp. 581-585
Closed Access | Times Cited: 3
Francesco Branda, Alessandra Ciccozzi, Chiara Romano, et al.
Infectious Diseases (2024) Vol. 56, Iss. 7, pp. 581-585
Closed Access | Times Cited: 3
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development
Fabrizio Angius, Silvia Puxeddu, S Zaimi, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 17-17
Open Access | Times Cited: 3
Fabrizio Angius, Silvia Puxeddu, S Zaimi, et al.
Vaccines (2024) Vol. 13, Iss. 1, pp. 17-17
Open Access | Times Cited: 3
Antibody evasion associated with the RBD significant mutations in several emerging SARS-CoV-2 variants and its subvariants
Manojit Bhattacharya, Srijan Chatterjee, Sang‐Soo Lee, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 101008-101008
Closed Access | Times Cited: 9
Manojit Bhattacharya, Srijan Chatterjee, Sang‐Soo Lee, et al.
Drug Resistance Updates (2023) Vol. 71, pp. 101008-101008
Closed Access | Times Cited: 9
Distinctive Features of the XBB.1.5 and XBB.1.16 Spike Protein Receptor-Binding Domains and Their Roles in Conformational Changes and Angiotensin-Converting Enzyme 2 Binding
Tej Sharma, Bernard S. Gerstman, Prem P. Chapagain
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12586-12586
Open Access | Times Cited: 6
Tej Sharma, Bernard S. Gerstman, Prem P. Chapagain
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 12586-12586
Open Access | Times Cited: 6
Engineered Multivalent Nanobodies Efficiently Neutralize SARS-CoV-2 Omicron Subvariants BA.1, BA.4/5, XBB.1 and BQ.1.1
Jiali Wang, Bingjie Shi, Hanyi Chen, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 417-417
Open Access | Times Cited: 1
Jiali Wang, Bingjie Shi, Hanyi Chen, et al.
Vaccines (2024) Vol. 12, Iss. 4, pp. 417-417
Open Access | Times Cited: 1
The diversification of SARS-CoV-2 Omicron variants and evaluation of their detection with molecular and rapid antigen assays
Mark Anderson, Vera Holzmayer, Barbara J. Harris, et al.
Journal of Clinical Virology (2023) Vol. 166, pp. 105532-105532
Open Access | Times Cited: 1
Mark Anderson, Vera Holzmayer, Barbara J. Harris, et al.
Journal of Clinical Virology (2023) Vol. 166, pp. 105532-105532
Open Access | Times Cited: 1
Engineered Therapeutic Antibody Against SARS-CoV-2
Monrat Chulanetra
Current Clinical Microbiology Reports (2023) Vol. 10, Iss. 4, pp. 222-235
Closed Access
Monrat Chulanetra
Current Clinical Microbiology Reports (2023) Vol. 10, Iss. 4, pp. 222-235
Closed Access
